Company intelligence / Profile preview
Convergent Therapeutics
Cambridge, Massachusetts, United Statesconvergentrx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Convergent Therapeutics has demonstrated efficacy and safety of its lead asset, CONV01‑α (Ac‑225 rosopatamab tetraxetan), in multiple Phase 1/2 trials for prostate cancer. The company recently began a new Phase II trial for this candidate. Its approach leverages targeted delivery of potent alpha radiation to tumor cells while sparing healthy tissue. Additional pipeline assets are at preclinical or early clinical stages targeting other solid tumors.
- Therapeutic areas
- Oncology
- Modalities
- Radiolabeled antibodies (radioantibodies)Therapeutic radiopharmaceuticalsMonoclonal antibodies conjugated with alpha emitters (e.g., Actinium‑225)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Convergent Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Convergent Therapeutics.